Dynamic Evaluation of an Active Axial Magnetic Levitated Bearing System in a Hemocompatibility Assessment Platform.
Dynamic Evaluation of an Active Axial Magnetic Levitated Bearing System in a Hemocompatibility Assessment Platform.
复制标题
血液相容性评估平台中主动轴向磁悬浮轴承系统的动态评估。
DOI：
10.1109/embc48229.2022.9871132
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Wang,Yaxin
中科院分区：
文献类型：
--
作者：
Kurita,Nobuyuki;Ogiwara,Eiji;Luo,Neil;Kiang,Simon;Karnik,Shweta;Smith,PAlex;Nissim,Lee;Fraser,KatherineH;Frazier,OH;Wang,Yaxin
为了评估我们的儿科左心室辅助装置（LVAD）各个组件的血液相容性，我们提出了一个带有磁悬浮轴承系统的血液相容性评估平台（HAP）。HAP由一个驱动系统组成，该驱动系统利用无刷直流（BLDC）电机、被动磁轴承（PMB）和主动磁悬浮轴承（AMB）来减少HAP本身产生的溶血。在这项研究中，我们通过测量径向不稳定力引起的转子的径向和轴向位移以及驱动系统在以每分钟1，200转（rpm）的速度旋转时的性能来设计和评估AMB的性能。结果表明，在径向扰动下，电磁轴承能够保持无刷直流电机系统的轴向稳定。AMB可以控制高达1，200 rpm，转子和定子之间没有任何接触。未来的工作包括几何优化的电磁轴承结构和提高能力，以控制稳定的高速旋转的整个系统。临床相关性-这项工作进一步开发了用于血液相容性评估平台的磁悬浮轴承系统，该平台将用于增强和加速成人和儿童LVAD的开发。
To evaluate the hemocompatibility of individual components of our pediatric left ventricular assist device (LVAD), we proposed a hemocompatibility assessment platform (HAP) with a magnetic levitated bearing system. The HAP consists of a drive system utilizing a brushless direct current (BLDC) motor, passive magnetic bearings (PMB), and an active magnetically levitated bearing (AMB) to reduce the hemolysis generated by HAP itself. In this study, we designed and evaluated the performance of the AMB by measuring radial and axial displacements of the rotor resulting from radially destabilizing forces as well as the performance of the drive system when rotated at increasing speeds to 1,200 rotations per minute (rpm). The results show that, with radial disturbance, the AMB is capable of maintaining axial stability for the BLDC motor system. The AMB can control up to 1,200 rpm without any contact between the rotor and stator. Future work includes geometry optimization for the AMB structure and increase the capability to control stable high-speed rotation for the entire system. Clinical Relevance— This work furthers the development of the magnetic levitated bearing system for a hemocompatibility assessment platform that will be used to enhance and accelerate the development of adult and pediatric LVADs.